News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
293,860 Results
Type
Article (14345)
Company Profile (109)
Press Release (279406)
Section
Business (97531)
Career Advice (468)
Deals (17436)
Drug Delivery (61)
Drug Development (39913)
Employer Resources (49)
FDA (7060)
Job Trends (6568)
News (166280)
Policy (15488)
Tag
Academia (518)
Africa (337)
Alliances (26563)
Alzheimer's disease (389)
Approvals (7047)
Arizona (38)
Artificial intelligence (47)
Asia (30362)
Australia (3928)
Bankruptcy (147)
Best Places to Work (4550)
Biosimilars (33)
Biotechnology (46)
Breast cancer (31)
C2C Services and Suppliers (15991)
California (754)
Canada (532)
Cancer (231)
Career advice (410)
Cell therapy (37)
China (97)
Clinical research (32848)
Collaboration (85)
Compensation (39)
Connecticut (33)
COVID-19 (848)
Data (183)
Diabetes (40)
Diagnostics (1683)
Drug pricing (53)
Earnings (34773)
Employer resources (43)
Europe (44686)
Events (40403)
Executive appointments (118)
FDA (7192)
Florida (97)
Funding (67)
Gene therapy (49)
GLP-1 (279)
Government (1391)
Healthcare (4207)
Hotbed/Location (192522)
Illinois (85)
Indiana (66)
Infectious disease (859)
Inflammatory bowel disease (49)
Interviews (58)
IPO (6647)
Japan (28)
Job creations (2134)
Job search strategy (378)
Kansas (53)
Layoffs (167)
Legal (3757)
Lung cancer (39)
Manufacturing (67)
Maryland (146)
Massachusetts (667)
Medical device (2230)
Medtech (2233)
Mergers & acquisitions (10763)
Metabolic disorders (132)
Minnesota (61)
Neuroscience (467)
New Jersey (320)
New York (239)
NextGen Class of 2024 (1726)
Non-profit (661)
North Carolina (264)
Northern California (332)
Obesity (82)
Ohio (35)
Opinion (108)
Patents (46)
Pennsylvania (225)
People (30246)
Pharmaceutical (63)
Phase I (8721)
Phase II (13976)
Phase III (12266)
Pipeline (77)
Podcasts (37)
Policy (40)
Postmarket research (1448)
Preclinical (3506)
Radiopharmaceuticals (127)
Rare diseases (64)
Real estate (2911)
Regulatory (10775)
Research institute (621)
Resumes & cover letters (55)
South America (549)
Southern California (330)
Startups (1847)
Texas (100)
United States (3376)
Vaccines (106)
Washington State (53)
Weight loss (65)
Date
Today (45)
Last 7 days (250)
Last 30 days (1015)
Last 365 days (14918)
2024 (11231)
2023 (16189)
2022 (22953)
2021 (23515)
2020 (22028)
2019 (16797)
2018 (13111)
2017 (15513)
2016 (14694)
2015 (17317)
2014 (13989)
2013 (11971)
2012 (12879)
2011 (13384)
2010 (12164)
293,860 Results for "gw pharmaceuticals ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.
Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.
June 6, 2024
·
3 min read
Press Releases
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split
September 26, 2024
·
3 min read
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Business
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Galmed Pharmaceuticals Ltd. announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission.
April 4, 2024
·
5 min read
Pharm Country
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today announced that it has called an extraordinary general meeting of its shareholders (the “Extraordinary General Meeting”), to be held on May 22, 2024, at 10:00 a.m., Israel time.
April 15, 2024
·
7 min read
Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services.
Aurigene Pharmaceutical Services Ltd. (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DEL technologies, entered into a strategic partnership.
April 19, 2024
·
3 min read
Press Releases
ReWalk Robotics Ltd. Finalizes Corporate Name Change to Lifeward Ltd.
September 12, 2024
·
4 min read
Business
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report
NRx Pharmaceuticals, Inc. today announced that its Asia Pacific strategic partner Lotus Pharmaceutical Co. Ltd (1975.TW) identified enrollment completion of the NRx clinical trial in bipolar depression as a material event in is February 7 financial filing.
February 9, 2024
·
3 min read
Press Releases
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
September 6, 2024
·
7 min read
Business
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced the advance of the first $5 million milestone payment based on the Company’s partnership agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW).
February 12, 2024
·
3 min read
1 of 29,386
Next
